Drug intelligence / Profile preview

ONO-7428

Development stage: Phase 1
Lead developer: Ono Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ONO-7428 is a first-in-class monoclonal antibody drug candidate that targets and inhibits the function of ONCOKINE-1—a novel tumor-derived protein implicated in cancer progression and resistance to immunotherapy. By binding to and inhibiting ONCOKINE-1, which acts on both cancer cells and immune cells to promote tumor growth and immune evasion, ONO-7428 is designed to exert antitumor effects. The drug was originally developed by NEX-I (South Korea), with exclusive worldwide development and commercialization rights acquired by Ono Pharmaceutical in March 2024. It is currently being evaluated in Phase 1 clinical trials for advanced or recurrent solid tumors.

Other names: ONO-7428ONO7428ONO 7428NXI-101NXI101NXI 101

Targets

CLEC2D (Lectin-like transcript 1)

Beyond the preview

Go deeper on ONO-7428.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONO-7428.

Explore the full profile